Exact Sciences Corporation (EXAS)

Market Cap	9.32B
Revenue (ttm)	2.53B
Net Income (ttm)	-240.23M
Shares Out	184.53M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,631,801
Open	51.95
Previous Close	51.95
Day's Range	50.35 - 51.95
52-Week Range	50.42 - 100.77
Beta	1.26
Analysts	Strong Buy
Price Target	90.42 (+79.48%)
Earnings Date	May 8, 2024

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Co...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 6,600
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAS

Financial Performance

In 2023, Exact Sciences's revenue was $2.50 billion, an increase of 19.93% compared to the previous year's $2.08 billion. Losses were -$204.15 million, -67.26% less than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price forecast is $90.42, which is an increase of 79.48% from the latest price.

Price Target

$90.42

(79.48% upside)

Analyst Consensus: Strong Buy